Schizophrenia | Magnetic Stimulation as a Treatment for Auditory Hallucinations in Schizophrenia
Schizophrenia research study
What is the primary objective of this study?
Schizophrenia is a chronic, severe, and disabling brain disease. Auditory hallucinations are the most frequent symptoms with an incident of 50% to 70% in patients. Transcranial Magnetic Stimulation (TMS) can significantly reduce symptoms of schizophrenia. TMS is capable of inducing changes in the electrical activities of the brain in humans. The purpose of this trial is to study the use of TMS to decrease auditory hallucinations in schizophrenia.
Who is eligible to participate?
Inclusion Criteria: - Schizophrenia - Auditory hallucinations occuring more than 5 times per day - Adequate (6 weeks) trial of antipsychotic medication - Including at least 1 atypical antipsychotic medication - Medication stable for 4 weeks prior to commencement of the study - Competent to consent Exclusion Criteria: - history of seizure disorder in patient or first degree relative - recent head injury - Acute suicidality - Alcohol or substance abuse - Implanted pacemaker or metal in head or neck - Pregnancy
Which medical condition, disease, disorder, syndrome, illness, or injury is researched?
Interventions can include giving participants drugs, medical devices, procedures, vaccines, and other products that are either investigational or already available or noninvasive approaches such as surveys, education, and interviews.
Device:Paired PulseTrue treatment with rTMS over the temporoparietal cortex.
Device:Paired PulseSham treatment with rTMS over the temporoparietal cortex.
Research studies and clinical trials typically have two or more research arms. An arm is a group of people who receive the same treatment in the study.
True Transcranial Magnetic StimulationTrue treatment with TMS over the temporoparietal cortex.
Sham Transcranial Magnetic StimulationSham treatment with rTMS over the temporoparietal cortex.
Start Date: November 2004
Completed Date: January 2015
Phase: Phase 4
Primary Outcome: Hoffman Auditory Hallucination Scale
Secondary Outcome: Positive and Negative Syndrome Scale for Schizophrenia (PANSS)
Study sponsors, principal investigator, and references
Principal Investigator: Gary Hasey, MD
Lead Sponsor: St. Joseph's Healthcare Hamilton